3-溴-1H-吡唑并[4,3-B]吡啶 | 633328-33-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 3-溴-1H-吡唑并[4,3-B]吡啶
• 英文名称: 3-bromo-1H-pyrazolo[4,3-b]pyridine
• 英文别名: 3-bromo-2H-pyrazolo[4,3-b]pyridine
• CAS: 633328-33-3
• 化学式: C₆H₄BrN₃
• 分子量: 198.022
• InChiKey: SXDNKFXWUFUOBP-UHFFFAOYSA-N

物化性质

• 沸点：
  366.9±22.0 °C(Predicted)
• 密度：
  1.894±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Bromo-1H-Pyrazolo[4,3-B]Pyridine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 198,02 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-Bromo-1H-Pyrazolo[4,3-B]Pyridine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-Bromo-1H-Pyrazolo[4,3-B]Pyridine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3-Bromo-1H-Pyrazolo[4,3-B]Pyridine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3-Bromo-1H-Pyrazolo[4,3-B]Pyridine)
IATA: Toxic solid, organic, n.o.s. (3-Bromo-1H-Pyrazolo[4,3-B]Pyridine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

简介

3-溴-1H-吡唑并[4,3-B]吡啶是一种有机中间体，可通过3-氟代-2-甲酰吡啶和肼反应制备得到。

制备

将3-氟代-2-甲酰吡啶（1.02克，8.15毫摩尔）与肼（2毫升）的混合物加热至110℃。反应16小时后，将反应混合物倾倒至冰水中，并用乙酸乙酯（3次，每次50毫升）萃取。收集有机层并用盐水（100毫升）洗涤，然后经过硫酸镁干燥、过滤和浓缩，最终得到一种暗褐色的油状物。

反应信息

• 作为反应物：
  描述：

  3-溴-1H-吡唑并[4,3-B]吡啶 在 tris-(dibenzylideneacetone)dipalladium(0) 4-二甲氨基吡啶 、 caesium carbonate 、 三乙胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 tert-butyl 3-((3-chlorophenyl)amino)-1H-pyrazolo[4,3-b]pyridine-1-carboxylate
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
  [FR] COMPOSÉS DE PYRAZOLOPYRIDINE, DE PYRAZOLOPYRAZINE, DE PYRAZOLOPYRIMIDINE, DE PYRAZOLOTHIOPHÈNE ET DE PYRAZOLOTHIAZOLE EN TANT QUE POTENTIALISATEURS ALLOSTÉRIQUES DU SOUS-TYPE 4 DU RÉCEPTEUR DU GLUTAMATE MÉTABOTROPIQUE (MGLUR4), COMPOSÉS ET PROCÉDÉS D

  摘要：

  吡唑吡啶，吡唑吡嗪，吡唑嘧啶，吡唑噻吩和吡唑噻唑化合物可用作代谢型谷氨酸受体亚型4（mGluR4）的别构势化剂/正别构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物的方法，例如用于治疗神经系统和精神疾病或其他与谷氨酸功能紊乱有关的疾病状态。

  公开号：

  WO2011100607A1
• 作为产物：
  描述：

  3-氟吡啶-2-醛 在 溴 、 sodium hydroxide 、 肼 作用下， 反应 19.0h， 生成 3-溴-1H-吡唑并[4,3-B]吡啶
  参考文献：
  名称：

  N-（3-氯-4-氟苯基）-1H-吡唑并[4,3-b]吡啶-3-胺（VU0418506），一种新型的代谢型谷氨酸受体正变构调节剂，其发现，合成和临床前表征（mGlu4）。

  摘要：

  许多小组已经确定了代谢型谷氨酸受体4（mGlu4）的正变构调节剂（PAM）在帕金森氏病的临床前啮齿动物模型中的功效。在这里，我们报告一个先进的临床前表征的mGlu4 PAM，N-（3-氯-4-氟苯基）-1H-吡唑并[4,3-b]吡啶-3-胺（VU0418506）。我们详细介绍了从常见的吡啶啉酰胺核心骨架开始的VU0418506的发现，并评估了导致新的吡唑并[4,3-b]吡啶头部基团的许多酰胺生物等排体。VU0418506被表征为在三种临床前安全物种中具有合适的体内药代动力学特性的有效且选择性的mGlu4 PAM。

  DOI：

  10.1021/acschemneuro.6b00035

文献信息

• RorgammaT inhibitors
  申请人：MSD Oss B.V.

  公开号：EP2487159A1

  公开（公告）日：2012-08-15

  The present invention relates to compounds according to general Formula I or a pharmaceutically acceptable salt thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及符合一般式I的化合物 或其药用可接受的盐。这些化合物可用于治疗RORgammaT介导的疾病或症状。
• [EN] NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR DE SOMATOSTATINE DE SOUS-TYPE 4 (SSTR4)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014184275A1

  公开（公告）日：2014-11-20

  The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

  这项发明涉及一般式(I)的3-aza-双环[3.1.0]己烷-6-羧酸酰胺衍生物，它们是生长抑素受体亚型4（SSTR4）的激动剂，用于预防或治疗与SSTR4相关的医学疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制备化合物的方法。
• [EN] 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS D'ACIDE BENZOÏQUE À SUBSTITUTION 4-HÉTÉROARYLE EN TANT QU'INHIBITEURS DE RORGAMMAT ET LEURS UTILISATIONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2014026327A1

  公开（公告）日：2014-02-20

  Provided are compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  根据公式I提供了化合物或其药用可接受的盐或溶剂。这些化合物可用于治疗RORgammaT介导的疾病或症状。
• Compounds as syk kinase inhibitors
  申请人：Almirall, S.A.

  公开号：EP2489663A1

  公开（公告）日：2012-08-22

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

  本发明涉及一种化合物（I）的公式，以及制备这种化合物的方法，以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病容易通过抑制Syk激酶而得到改善。
• [EN] 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(2- (HÉTÉROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMÉTHYL) -1,2,4-OXADIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE HDAC6
  申请人：ORYZON GENOMICS SA

  公开号：WO2020245381A1

  公开（公告）日：2020-12-10

  The invention relates to compounds as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

  这项发明涉及作为组织脱乙酰化酶6（HDAC6）抑制剂的化合物。该发明还涉及包含这些化合物的药物组合物以及它们在治疗中的应用。